Dana-Farber, Gladstone Institutes join Parker Institute network

Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy

In 1989, I stood in front of the AIDS Memorial Quilt on a hot summer afternoon on the National Mall in Washington DC.

June 12, 2026

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.

June 05, 2026

Vol.52 No.22

By W. Kimryn Rathmell

In Brief

Aimee Johnson named chief marketing officer of Parker Institute

Aimee Johnson was named chief marketing officer of the Parker Institute for Cancer Immunotherapy.

May 08, 2026

Vol.52 No.18

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.

Parker Institute for Cancer Immunotherapy and Cancer Vaccine Coalition join to accelerate cancer prevention and treatment

The Parker Institute for Cancer Immunotherapy announced a strategic integration with the Cancer Vaccine Coalition, a nonprofit dedicated to advancing next-generation cancer immunotherapies, to accelerate the development and delivery of cancer vaccines, one of the most promising frontiers in cancer research.

April 17, 2026

Vol.52 No.15

In Brief

Bolyn Hubby named chief of staff at PICI

Bolyn Hubby was named chief of staff at the Parker Institute for Cancer Immunotherapy.

April 03, 2026

Vol.52 No.13

Dana-Farber, Gladstone Institutes join Parker Institute network

YOU MAY BE INTERESTED IN

Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Aimee Johnson named chief marketing officer of Parker Institute

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Parker Institute for Cancer Immunotherapy and Cancer Vaccine Coalition join to accelerate cancer prevention and treatment

Bolyn Hubby named chief of staff at PICI

Renew today!

Subscriber content

Never miss an issue!

Login

Dana-Farber, Gladstone Institutes join Parker Institute network

YOU MAY BE INTERESTED IN

Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy

The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Aimee Johnson named chief marketing officer of Parker Institute

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

Parker Institute for Cancer Immunotherapy and Cancer Vaccine Coalition join to accelerate cancer prevention and treatment

Bolyn Hubby named chief of staff at PICI

Never miss an issue!

Login

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”